GENX Stock Overview
Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genex Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -98.39% |
| 5 Year Change | -98.89% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| GENX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | -2.6% |
| 1Y | 0% | 9.9% | 24.5% |
Return vs Industry: GENX exceeded the US Medical Equipment industry which returned -1.8% over the past year.
Return vs Market: GENX underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| GENX volatility | |
|---|---|
| GENX Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GENX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GENX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Fuzhi Song | n/a |
Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People’s Republic of China. The RBX is a medical device that accelerates bone healing. The company distributes its medical devices to approximately 500 hospitals, as well as to other medical device customers.
Genex Pharmaceutical, Inc. Fundamentals Summary
| GENX fundamental statistics | |
|---|---|
| Market cap | US$1.78k |
| Earnings (TTM) | US$342.55k |
| Revenue (TTM) | US$3.24m |
0.0x
P/E Ratio0.0x
P/S RatioIs GENX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENX income statement (TTM) | |
|---|---|
| Revenue | US$3.24m |
| Cost of Revenue | US$362.72k |
| Gross Profit | US$2.87m |
| Other Expenses | US$2.53m |
| Earnings | US$342.55k |
Last Reported Earnings
Dec 31, 2007
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did GENX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/13 04:24 |
| End of Day Share Price | 2023/09/15 00:00 |
| Earnings | 2007/12/31 |
| Annual Earnings | 2007/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genex Pharmaceutical, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|